

Special Issue

Diagnosis, Pathogenesis and Treatment of Central Nervous System Injuries

Message from the Guest Editor

CNS injuries very often referred as “The most complex disease of the most complex organ”. As a consequence of that, meanwhile even the diagnostic – as well as the prognostic – tools can be improved (among others by the more widespread utilization or inclusion of the protein biomarkers), there is practically still no causal, individualized therapy exists, especially for the consequences of mild or repetitive mild TBI. One substantial reason is the fact that many of those pathophysiological processes which led to the long term consequences are still unknown.

In light of the above we intended this special issue as a collection of experimental studies as well as reviews which would elucidate the still existing many knowledge gaps in the diagnosis, pathology and pathophysiology of the CNS injuries and/or facilitate more specific and effective therapeutic interventions.

Guest Editor

Dr. Endre Czeiter

1. Department of Neurosurgery, Medical School, University of Pecs, H-7623 Pecs, Hungary
2. Neurotrauma Research Group, Szentagothai Research Centre, University of Pecs, H-7624 Pecs, Hungary
3. ELKH-PTE Clinical Neuroscience MR Research Group, H-7623 Pecs, Hungary

Deadline for manuscript submissions

closed (15 November 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/71663

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).